Surveillance Imaging for Squamous Cell Carcinoma of the Soft Palate After Definitive Radiation

Initial Post-Treatment Baseline Imaging

Obtain PET/CT at 8-12 weeks after completion of definitive radiation therapy as the optimal baseline surveillance imaging, allowing for resolution of acute inflammatory changes while maintaining high negative predictive value for detecting residual disease, according to the American College of Radiology 1
PET/CT provides both metabolic and anatomic information, making it more accurate than either modality alone for head and neck squamous cell carcinoma surveillance, as recommended by the American College of Radiology 1

If the 8-12 week PET/CT is negative, obtain either contrast-enhanced CT or PET/CT at 6 months post-treatment, as suggested by the American College of Radiology 1
If the 6-month imaging is negative, perform contrast-enhanced CT of the neck every 6 months through 24 months, according to the American College of Radiology 1
If two consecutive PET/CT studies are scored as NI-RADS 1, no further routine surveillance imaging is needed, as 95% of asymptomatic recurrences are detected within the first 24 months, as stated by the American College of Radiology 1

Perform clinical follow-up with flexible endoscopy every 2-3 months during the first 2 years, as recommended by the European Society for Medical Oncology 2
Every 6 months for years 3-5, and annually thereafter, as suggested by the European Society for Medical Oncology 2
The soft palate requires careful endoscopic visualization as submucosal recurrences cannot be detected by visual inspection alone, according to the American College of Radiology 1

PET/CT is preferred over other modalities because it has superior sensitivity for detecting recurrence in head and neck squamous cell carcinoma compared to CT or MRI alone, as recommended by the American College of Radiology 1
Contrast-enhanced CT is appropriate for follow-up imaging after negative baseline PET/CT, as suggested by the American College of Radiology 1

Obtain imaging immediately if symptoms develop or clinical examination reveals abnormalities, regardless of the surveillance schedule, as recommended by the European Society for Medical Oncology 2
Do not wait for the next scheduled surveillance timepoint if clinical suspicion arises, according to the European Society for Medical Oncology 2

Monitor thyroid function (TSH) at 1, 2, and 5 years post-radiation, as the soft palate treatment field typically includes thyroid exposure, as suggested by the European Society for Medical Oncology 2
Consider annual chest imaging for patients with significant smoking history to screen for second primary lung cancer, according to the American Academy of Otolaryngology-Head and Neck Surgery 5